Journal
CHEMMEDCHEM
Volume 8, Issue 7, Pages 1138-1160Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/cmdc.201300050
Keywords
enoyl reductase; inhibitors; medicinal chemistry; Toxoplasma gondii; triclosan
Categories
Funding
- NIAID [U01 AI082180-01]
- MRC [G1000567]
- Rooney-Alden family
- Taub family
- Engel family
- Pritzker family
- Harris family
- Mussilami family
- Samuel family
- Mann-Cornwell Family Foundation
- Medical Research Council [G1000567] Funding Source: researchfish
- MRC [G1000567] Funding Source: UKRI
Ask authors/readers for more resources
Through our focused effort to discover new and effective agents against toxoplasmosis, a structure-based drug design approach was used to develop a series of potent inhibitors of the enoyl-acyl carrier protein (ACP) reductase (ENR) enzyme in Toxoplasma gondii (TgENR). Modifications to positions 5 and 4 of the well-known ENR inhibitor triclosan afforded a series of 29 new analogues. Among the resulting compounds, many showed high potency and improved physicochemical properties in comparison with the lead. The most potent compounds 16a and 16c have IC50 values of 250nM against Toxoplasma gondii tachyzoites without apparent toxicity to the host cells. Their IC50 values against recombinant TgENR were found to be 43 and 26nM, respectively. Additionally, 11 other analogues in this series had IC50 values ranging from 17 to 130nM in the enzyme-based assay. With respect to their excellent invitro activity as well as improved drug-like properties, the lead compounds 16a and 16c are deemed to be excellent starting points for the development of new medicines to effectively treat Toxoplasma gondii infections.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available